1. Home
  2. MTDR vs BLTE Comparison

MTDR vs BLTE Comparison

Compare MTDR & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MTDR

Matador Resources Company

HOLD

Current Price

$60.21

Market Cap

6.8B

Sector

Energy

ML Signal

HOLD

Logo Belite Bio Inc

BLTE

Belite Bio Inc

HOLD

Current Price

$147.72

Market Cap

6.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MTDR
BLTE
Founded
2003
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.8B
6.0B
IPO Year
2011
2021

Fundamental Metrics

Financial Performance
Metric
MTDR
BLTE
Price
$60.21
$147.72
Analyst Decision
Buy
Strong Buy
Analyst Count
22
9
Target Price
$69.71
★ $228.89
AVG Volume (30 Days)
★ 1.2M
133.0K
Earning Date
11-03-2026
11-09-2026
Dividend Yield
★ 3.08%
N/A
EPS Growth
N/A
★ N/A
EPS
★ 2.86
N/A
Revenue
★ $3,696,277,000.00
N/A
Revenue This Year
$16.02
N/A
Revenue Next Year
$15.94
N/A
P/E Ratio
$19.83
★ N/A
Revenue Growth
★ 5.46
N/A
52 Week Low
$37.14
$90.84
52 Week High
$66.84
$200.00

Technical Indicators

Market Signals
Indicator
MTDR
BLTE
Relative Strength Index (RSI) 65.27 39.67
Support Level $52.15 $145.21
Resistance Level $60.38 $161.08
Average True Range (ATR) 1.79 5.89
MACD 0.62 -0.37
Stochastic Oscillator 91.81 30.70

Price Performance

Historical Comparison
MTDR
BLTE

About MTDR Matador Resources Company

Matador Resources Co is an independent energy company engaged in the exploration, development, production, and acquisition of oil and natural gas resources. The majority of the company's assets are located in the United States, with an emphasis on oil and natural gas shale and other unconventional plays. Along with maintaining a portfolio of oil and natural gas properties, Matador works to identify and develop midstream opportunities that support and enhance its exploration and development business. The Company has two reportable business segments: exploration and production and midstream. The company generates majority of its revenue from the exploration and production segment.

About BLTE Belite Bio Inc

Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.

Share on Social Networks: